The investigators sought to evaluate whether early-life traumatic experiences, stressful life events, and alexithymia are associated with chronic migraine and medication overuse headache.
Individuals with chronic vs episodic migraine may be more likely to experience chronic back pain, chronic pain, neck pain, anxiety, and depression.
Researchers deployed a survey to determine the extent of pain, psychiatric, endocrine, and neurologic comorbidities in patients with chronic or episodic migraine.
For patients with chronic migraine, onabotulinumtoxinA was shown to have a better outcome.
Both erenumab and fremanezumab are currently under review by the FDA for the treatment of migraine.
Acupressure is not a beneficial adjunctive therapy to sodium valproate for the treatment of chronic migraine with aura.
More targeted injection sites may improve efficacy and the overall patient experience in chronic migraine.
The majority of centers follow protocols for administration of onabotulinumtoxinA.
A growing body of research indicates a number of shared features between chronic migraine and temporomandibular disorders.
In chronic migraine and medication overuse, those who frequently relapse into overuse after withdrawal have a worse clinical and psychological profile than patients who relapse less frequently.
During headache, patients with chronic migraine had greater activity in the right anterior hypothalamic region than patients with episodic or no migraine.
The study found a strong link between chronic migraine and psychological symptoms and beliefs that contribute to disability.
Remote electrical stimulation appears to have similar efficacy to standard drug treatments, including triptans.
Patients with chronic migraine and comorbidities incur nearly 2 times the health care costs incurred by patients with migraine alone.
A larger percentage of participants receiving CBT plus amitriptyline reached a 50% reduction in migraine frequency during treatment compared with HE plus amitriptyline.
Recovery time varies depending on which class of medication the patient is overusing.
Acupuncture, neurostimulation, and other alternative treatments have been associated with up to a 50% reduction in headache days.
A 30% or greater decline in mean monthly moderate-to-severe headache days was met by 45.3 % (n=24) of patients treated with occipital nerve stimulation.
Patients in both groups were satisfied with their care.
Previous analysis showed that treatment reduced chronic migraine frequency.
Participants experienced a reduction in headache days as soon as 3 days post-treatment.
Treatment of chronic, but not episodic migraine with botulinum toxin has been added to the treatment guidelines.
Neurology Advisor Articles
- OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms
- History of Migraine Associated With Higher Risk for Cochlear Disorders
- Patent Foramen Ovale Closure for Stroke Prevention: Key Principles for Clinical Practice
- Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits
- A Model for Predicting Quality of Life Improvements After Deep Brain Stimulation
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- FDA Grants Orphan Drug Status to Angelman Syndrome Treatment
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Clinical, Radiologic Markers Predictive of Cortical Superficial Siderosis in ICH Identified
- Migraine Pain Location May Not Have Clinical Implications